AbbVie Inc. /
Cerevel Therapeutics Holdings, Inc.
AbbVie completes merger with Cerevel Therapeutics Holdings, Inc.
What happened
AbbVie Inc. completed its merger with Cerevel Therapeutics Holdings, Inc. on Aug. 1, 2024, making Cerevel a wholly owned subsidiary of AbbVie.
Cerevel stockholders received $45.00 per share in cash, subject to applicable withholding taxes.
The source
Everything on this page comes from the source below.
AbbVie completes merger with Cerevel Therapeutics Holdings, Inc.
This document is the source for the companies, stage, figure and people on this page.
Source-verifiedTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly